A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
Study Details
Study Description
Brief Summary
The purpose of this study is to demonstrate the non-inferiority of a heterologous prime-boost regimen using Ad26.ZEBOV as prime and MVA-BN-Filo as boost administered at different doses at a 56-day interval versus the same regimen with the recently released batches of Ad26.ZEBOV and MVA-BN-Filo in terms of humoral immune response against the Ebola virus (EBOV) GP (glycoprotein) as measured by enzyme-linked immunosorbent assay (ELISA) at 21 days post boost.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate safety and immunogenicity of Ad26.ZEBOV and MVA-BN-Filo at different dose levels, administered to healthy adults participants. The study consists of a Screening period of up to 6 weeks, vaccinations on Day 1 and Day 57, and a post-vaccination phase until the 6 months post-boost visit (Day 237). The participants will be randomized at baseline (on Day 1) in a 2:2:2:1 ratio to Groups 1, 2, 3 and 4. Safety will be monitored throughout the study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Group 1 Ad26.ZEBOV 5*10^10 viral particles (vp) single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] single dose IM injection on Day 57 |
Biological: Ad26.ZEBOV 5*10^10 viral particles (vp)
Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 5*10^10 viral particles on Day 1
Biological: MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]
MVA-BN-Filo- live replication incompetent vaccine, IM injection of 1*10^8 Infectious Unit [Inf. U.] once on Day 57
|
| Experimental: Group 2 Ad26.ZEBOV 2*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf. U single dose IM injection on Day 57 |
Biological: Ad26.ZEBOV 2*10^10 (vp)
Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 2*10^10 viral particles on Day 1
Biological: MVA-BN-Filo 5*10^7 Inf. U.
MVA-BN-Filo- live replication incompetent vaccine, IM injection of 5*10^7 Inf. U. once on Day 57
|
| Experimental: Group 3 Ad26.ZEBOV 0.8*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf. U. single dose IM injection on Day 57 |
Biological: Ad26.ZEBOV 0.8*10^10 (vp)
Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 0.8*10^10 viral particles on Day 1
Biological: MVA-BN-Filo 5*10^7 Inf. U.
MVA-BN-Filo- live replication incompetent vaccine, IM injection of 5*10^7 Inf. U. once on Day 57
|
| Experimental: Group 4 Participants will receive intramuscular (IM) injection of Placebo (0.9% saline) once on Day 1 and Day 57 |
Biological: Placebo
One 0.5 ml IM injection of 0.9% saline administered once on Day 1 and Day 57
|
Outcome Measures
Primary Outcome Measures
- Immune Responses to the Study Vaccine Regimens against Ebola virus (EBOV) Glycoprotein (GP) using EBOV GP protein Enzyme-linked Immunosorbent Assay (ELISA) [At 21 days post boost vaccination]
The humoral immune response will be assessed by enzyme-linked immunosorbent assay (ELISA) binding antibody
Secondary Outcome Measures
- Immune Responses to the Study Vaccine Regimens against Ebola virus (EBOV) Glycoprotein (GP) using EBOV GP protein Enzyme-linked Immunosorbent Assay (ELISA) [At Days 1, 29, 57 post prime dose and at days 42, and 180 post boost vaccination]
The humoral immune response will be assessed by enzyme-linked immunosorbent assay (ELISA) binding antibody
- Number of Participants with Solicited Local and Systemic Adverse Events (AEs) [Up to 7 days after each vaccination]
- Number of Participants with Adverse Events (AEs) [Up to 42 days post boost vaccination]
- Number of Participants with Serious Adverse Events (SAEs) [Continuous throughout the duration of study (Up to Day 237)]
Eligibility Criteria
Criteria
Inclusion criteria :
-
Must be healthy in the Investigator's clinical judgment on the basis of medical history, physical examination, electrocardiogram (ECG) and vital signs performed at Screening
-
Must be healthy on the basis of clinical laboratory tests performed at Screening
-
Before randomization, a woman must be either of childbearing potential and practicing (or intending to practice) a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for participants participating in clinical studies, beginning at least 28 days prior to vaccination OR not of childbearing potential: postmenopausal [greater than (>)] 45 years of age with amenorrhea for at least 2 years or any age with amenorrhea for at least 6 months, and a serum follicle stimulating hormone (FSH) level >40 international unit per milliliter (IU/L); permanently sterilized (for example, bilateral tubal occlusion [which includes tubal ligation procedures as consistent with local regulations], hysterectomy, bilateral salpingectomy, bilateral oophorectomy); or otherwise be incapable of pregnancy
-
Woman of childbearing potential must have a negative serum [beta-human chorionic gonadotropin (beta-hCG)] at Screening and a negative urine beta-hCG pregnancy test immediately prior to each study vaccine administration
-
Man who is sexually active with a woman of childbearing potential and has not had a vasectomy performed more than 1 year prior to Screening must be willing to use condoms for sexual intercourse beginning prior to enrollment, in addition to the birth control method used by the female partner
Exclusion criteria:
-
Having received a candidate Ebola vaccine
-
Diagnosed with Ebola virus disease, or prior exposure to Ebola virus, including travel to West Africa less than 1 month prior to Screening. West Africa includes but is not limited to the countries of Guinea, Liberia, Mali, and Sierra Leone
-
Having received any experimental candidate adenovirus serotype 26 (vector: Ad26) or Modified Vaccinia Ankara (MVA)- based vaccine in the past
-
Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products (including any of the constituents of the study vaccines) including known allergy to egg, egg products and aminoglycosides
-
Presence of acute illness or temperature greater than or equal to (>=) 38.0 (°C) centigrade on Day 1
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Huntsville | Alabama | United States | ||
| 2 | San Diego | California | United States | ||
| 3 | Melbourne | Florida | United States | ||
| 4 | Peoria | Illinois | United States | ||
| 5 | Mishawaka | Indiana | United States | ||
| 6 | Rockville | Maryland | United States |
Sponsors and Collaborators
- Janssen Vaccines & Prevention B.V.
Investigators
- Study Director: Janssen Vaccines & Prevention B.V. Clinical Trial, Janssen Vaccines & Prevention B.V.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CR107861
- VAC52150EBL3002